WOLLAEC Form 4	GER TIMOTHY J												
November	16, 2005												
FORM 4 UNITED STATES SECURITIES AND EXCHANGE						NGE (	COMMISSIO	N	OMB APPROVAL				
			Washington, D.C. 20549							-	OMB Number	: 32	235-0287
Check t if no lor subject Section Form 4 Form 5 obligati may co	CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES ection 16(a) of the Securities Exchange Act of 1934, Public Utility Holding Company Act of 1935 or Section of the Investment Company Act of 1940							,	January 31, 2005 Estimated average burden hours per response 0.5				
<i>See</i> Inst 1(b).	ruction	20(11)	or the r	ii ( estille		company	1100	. 01 17					
(Print or Type	Responses)												
	Address of Reporting GER TIMOTHY		Symbol			I Ticker or T P [DRAD]		g	5. Relationship Issuer	of I	Reporting 1	Person(s	) to
(Last)	(First) (	Middle)		of Earliest					(Ch	neck	all applica	able)	
C/O KING				Day/Year)		ansaction			X Director Officer (gi below)	ive ti		10% Own Other (spe	
	(Street)			endment, onth/Day/Y		ate Original			6. Individual or Applicable Line) _X_ Form filed b Form filed b	y Oi	ne Reporting	g Person	
	GO, CA 92121								Person			Ĩ	0
(City)	(State)	(Zip)	Tał	ole I - Nor	n-D	<b>Derivative S</b>	ecuri	ties Ac	quired, Disposed	of,	or Benefi	cially O	wned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transact Code (Instr. 8) Code V	tior )	4. Securities (A) or Disp (Instr. 3, 4 a Amount	osed o	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	Fo Di or (I)	wnership orm: rect (D) Indirect	7. Natu Indirec Benefic Owners (Instr. 4	t cial ship
Common	11/15/2005			<b>J</b> (1)		497,885	D	<u>(2)</u>	0	Ι		By Kings	•
Stock	11/13/2003			J <u>('')</u>		497,003	U	(2)	0	1		Capita Partne II <u>(3)</u>	ers, L.P.
Common Stock	11/15/2005			J <u>(1)</u>		3,207	A	<u>(2)</u>	72,119 <u>(4)</u>	Ι		J. Wo and C K. Wolla	mothy llaeger ynthia leger, es, U/A

			DTD 4/25/1985							
Common Stock	685	Ι	By Kingsbury Associates, L.P. ( <u>3)</u>							
Common Stock	306,436	I	By Kingsbury Capital Partners, L.P. III ( <u>3)</u>							
Common Stock	339,766	I	By Kingsbury Capital Partners, L.P. IV (3)							
Common Stock	104,428	I	By Sanderling V Biomedical, L.P. (5)							
Common Stock	42,250	I	By Sanderling V Limited Partnership							
Common Stock	426,330	I	By Sanderling Venture Partners V, L.P. (5)							
Common Stock	37,594	I	By Sanderling V Beteiligungs GmbH & Co. KG (5)							
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.										
Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02) required to respond unless the form displays a currently valid OMB control number.										
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned   (e.g., puts, calls, warrants, options, convertible securities)										
	4.5.6. Date ExercisableTransactionNumberExpiration Date	e and 7. Titl Amou								

Security (Instr. 3)	or Exercise Price of Derivative Security	any (Month/Day/Year)	Code (Instr. 8)	Securities	Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3,		Secur	rlying itties . 3 and 4)	Security (Instr. 5)	Secur Bene Own Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## **Reporting Owners**

Reporting Owner Name / Address				
	Director	10% Owner	Officer	Other
WOLLAEGER TIMOTHY J C/O KINGSBURY ASSOCIATES 4401 EASTGATE MALL SAN DIEGO, CA 92121	Х			
Signatures				
Vera P. Pardee, by Power of Attorney	1			
**Signature of Reporting Person		Date		

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

On 11/15/05, Kingsbury Capital Partners, L.P. II commenced a liquidating distribution to its partners of an aggregate of 497,885 shares of common stock of the issuer, 5,010 shares of which were received by the general partner of Kingsbury Capital Partners, L.P. II, Kingsbury

- (1) Associates, L.P. In turn, Kingsbury Associates, L.P. distributed the 5,010 shares of common stock of the issuer to its partners, 3,207 of which were received by the reporting person. In prior reports, the reporting person reported beneficial ownership of 497,885 shares held by Kingsbury Capital Partners, L.P. II.
- (2) Not applicable.

The reporting person is the general partner of Kingsbury Associates, L.P., which is a general partner of each of Kingsbury Capital Partners, L.P. II, Kingsbury Capital Partners, L.P., IV. The reporting person disclaims beneficial automation of the charge hold by Kingsbury Capital Partners, L.P. III and Kingsbury Capital Partners, L.P., IV. The reporting person disclaims beneficial automation of the charge hold by Kingsbury Capital Partners, L.P. III and Kingsbury Capital Partners, L.P., IV. The reporting person disclaims beneficial automation of the charge hold by Kingsbury Capital Partners, L.P. III and Kingsbury Capital Partners, L.P., IV.

- (3) ownership of the shares held by Kingsbury Capital Partners, L.P. III and Kingsbury Capital Partners, L.P., IV, except to the extent of his pecuniary interests in the named fund. As general partner, the reporting person has voting and investment power with respect to the shares held by Kingsbury Capital Partners, L.P. III and Kingsbury Capital Partners, L.P., IV.
- (4) Includes 68,912 shares previously transferred by the reporting person to By Timothy J. Wollaeger and Cynthia K. Wollaeger, trustees, U/A DTD 4/25/1985.

The reporting person is the managing director of Middleton, McNeil & Mills Associates V, LLC, the general partner of Sanderling Venture Partners V, L.P., Sanderling V Biomedical, L.P., Sanderling V Limited Partnership and Sanderling V Beteiligungs GmbH & Co. KG. The reporting person disclaims beneficial ownership of the shares held by Sanderling Venture Partners V, L.P., Sanderling V

(5) Biomedical, L.P., Sanderling V Limited Partnership and Sanderling V Beteiligungs GmbH & Co. KG, except to the extent of his pecuniary interests in the named fund. The reporting person shares voting and investment power with respect to the shares held by Sanderling Venture Partners V, L.P., Sanderling V Biomedical, L.P., Sanderling V Limited Partnership and Sanderling V Beteiligungs GmbH & Co. KG with the other managing directors of Middleton, McNeil & Mills Associates V, LLC.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.